Alnylam reports five‑year HELIOS‑B data showing sustained benefits of AMVUTTRA in ATTR‑CM
Alnylam Pharmaceuticals presented five‑year results from the HELIOS‑B study at the American Heart Association Scientific Sessions 2026. Continuous treatment with AMVUTTRA (vutrisiran) reduced the composite of all‑cause mortality and recurrent cardiovascular events by 48% in the monotherapy cohort and 41% in the overall cohort versus delayed treatment. Patients also maintained better quality‑of‑life scores, stable cardiac biomarkers and a safety profile consistent with earlier reports.
Why it matters
The data provide long‑term efficacy and safety evidence for AMVUTTRA, supporting its use early in ATTR‑CM and potentially strengthening the product’s market positioning. Investors may view the results as a catalyst for future sales growth and reimbursement discussions.
Key facts
- 1Continuous AMVUTTRA treatment reduced the risk of all‑cause mortality and recurrent cardiovascular events by 48% in the monotherapy population. finance.yahoo.com
- 2In the overall study population, continuous treatment reduced the same composite risk by 41%. finance.yahoo.com
- 3Recurrent cardiovascular events alone were reduced by 50% in the monotherapy group and 41% in the overall group. finance.yahoo.com
- 4Patients receiving early treatment showed better Kansas City Cardiomyopathy Questionnaire Overall Summary scores and more stable NT‑proBNP and troponin I levels. finance.yahoo.com
- 5The safety profile over 60 months remained consistent with no new safety signals identified. finance.yahoo.com
- 6Alnylam’s stock closed at $156.61 on the day the results were reported. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.